Literature DB >> 24412054

Common data items in seven European oesophagogastric cancer surgery registries: towards a European upper GI cancer audit (EURECCA Upper GI).

W O de Steur1, D Henneman1, W H Allum2, J L Dikken3, J W van Sandick4, J Reynolds5, C Mariette6, L Jensen7, J Johansson8, P Kolodziejczyk9, R H Hardwick10, C J H van de Velde11.   

Abstract

AIMS: Seven countries (Denmark, France, Ireland, the Netherlands, Poland, Sweden, United Kingdom) collaborated to initiate a EURECCA (European Registration of Cancer Care) Upper GI project. The aim of this study was to identify a core dataset of shared items in the different data registries which can be used for future collaboration between countries.
METHODS: Item lists from all participating Upper GI cancer registries were collected. Items were scored 'present' when included in the registry, or when the items could be deducted from other items in the registry. The definition of a common item was that it was present in at least six of the seven participating countries.
RESULTS: The number of registered items varied between 40 (Poland) and 650 (Ireland). Among the 46 shared items were data on patient characteristics, staging and diagnostics, neoadjuvant treatment, surgery, postoperative course, pathology, and adjuvant treatment. Information on non-surgical treatment was available in only 4 registries.
CONCLUSIONS: A list of 46 shared items from seven participating Upper GI cancer registries was created, providing a basis for future quality assurance and research in Upper GI cancer treatment on a European level.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EURECCA; Esophgeal cancer; Gastric cancer; Quality assurance; Upper gastro intestinal surgery

Mesh:

Year:  2013        PMID: 24412054     DOI: 10.1016/j.ejso.2013.11.021

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.

Authors:  K E Mulder; S Ahmed; J D Davies; C M Doll; S Dowden; S Gill; V Gordon; P Hebbard; H Lim; A McFadden; J P McGhie; J Park; R Wong
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

2.  ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).

Authors:  J V Reynolds; S R Preston; B O'Neill; L Baeksgaard; S M Griffin; C Mariette; S Cuffe; M Cunningham; T Crosby; I Parker; K Hofland; G Hanna; L B Svendsen; C L Donohoe; C Muldoon; D O'Toole; C Johnson; N Ravi; G Jones; A K Corkhill; M Illsley; J Mellor; K Lee; M Dib; V Marchesin; M Cunnane; K Scott; P Lawner; S Warren; S O'Reilly; G O'Dowd; G Leonard; B Hennessy; R Mc Dermott
Journal:  BMC Cancer       Date:  2017-06-03       Impact factor: 4.430

Review 3.  What are the essential features of a successful surgical registry? a systematic review.

Authors:  Rishi Mandavia; Alec Knight; John Phillips; Elias Mossialos; Peter Littlejohns; Anne Schilder
Journal:  BMJ Open       Date:  2017-09-24       Impact factor: 2.692

4.  International benchmarking in oesophageal and gastric cancer surgery.

Authors:  L A D Busweiler; M Jeremiasen; B P L Wijnhoven; M Lindblad; L Lundell; C J H van de Velde; R A E M Tollenaar; M W J M Wouters; J W van Sandick; J Johansson; J L Dikken
Journal:  BJS Open       Date:  2018-10-19

5.  The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers.

Authors:  Ashika D Maharaj; Jennifer F Holland; Ri O Scarborough; Sue M Evans; Liane J Ioannou; Wendy Brown; Daniel G Croagh; Charles H C Pilgrim; James G Kench; Lara R Lipton; Trevor Leong; John J McNeil; Mehrdad Nikfarjam; Ahmad Aly; Paul R Burton; Paul A Cashin; Julie Chu; Cuong P Duong; Peter Evans; David Goldstein; Andrew Haydon; Michael W Hii; Brett P F Knowles; Neil D Merrett; Michael Michael; Rachel E Neale; Jennifer Philip; Ian W T Porter; Marty Smith; John Spillane; Peter P Tagkalidis; John R Zalcberg
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.